Payment Orchestration Platform Leader IXOPAY Appoints Suzanne Rudnitzki as President & Chief Operating Officer
Rudnitzki joins IXOPAY to accelerate growth and transform the global payments industry
TULSA, OK / ACCESSWIRE / October 25, 2024 / IXOPAY, a leading provider of enterprise-grade payment orchestration, announced the appointment of Suzanne Rudnitzki as President & Chief Operating Officer. The appointment strengthens IXOPAY's ability to lead the global payments industry to a global multiprocessor architecture.
IXOPAY Logo
Rudnitzki, a former private equity executive and Executive in Residence at IXOPAY, played a key role in IXOPAY's strategic merger with TokenEx earlier this year and in assembling new leaders to seize the growing payment orchestration market opportunity.
Rudnitzki will work with IXOPAY CEO Brady Harris and the broader leadership team, including recently appointed CTO Ronnie Thomson and CCO Kelly Wenzel, to optimize and scale IXOPAY's payment orchestration platform and payment optimization modules for customers worldwide.
"IXOPAY is disrupting the global payments industry by addressing a critical issue - the need for seamless integration across multiple payment service providers," said Rudnitzki. "Merchants are increasingly adopting a multiprocessor strategy with IXOPAY's enterprise-grade payment orchestration platform - boosting both their top and bottom line via increased authorization rates, enhanced security, and improved customer retention. I'm proud to become a permanent part of the team driving this global payments transformation."
"We're thrilled to welcome Suzanne Rudnitzki as President and Chief Operating Officer. With Suzanne's leadership, we will sharpen our operational strategy and position IXOPAY as the global leader in payment orchestration," said Brady Harris, CEO of IXOPAY. "Her experience scaling software companies and driving growth through strategic mergers and acquisitions will be invaluable as IXOPAY leads the payments industry toward a global multiprocessor future."
Rudnitzki is a highly experienced executive in the fintech and SaaS sectors, formerly serving as Chief Operating Officer at Smarsh, a global leader in financial compliance technology. There she led international teams across the U.S., UK, and India, while playing a central role in executing strategic mergers and acquisitions, and driving operational efficiency.
She will join IXOPAY CEO Brady Harris at Money20/20 in Las Vegas from October 27-30, where they will discuss IXOPAY's innovative solutions and future growth plans. Attendees interested in learning more are encouraged to connect with them during the event at Booth #11213.
About IXOPAY
IXOPAY is a leading provider of enterprise-grade payment orchestration, providing a fully integrated platform and flexible payment optimization modules to businesses around the world. With a single API and scalable payments architecture, IXOPAY empowers businesses to simplify, secure and increase the resilience of their payment systems. Learn more at www.ixopay.com.
Contact Information
Mills Forni
Partner, Verdis
mills@verdis.xyz
+1 802-335-2603
Related Images
|
SOURCE: IXOPAY
View the original press release on newswire.com.
IXOPAY
Subscribe to releases from Accesswire
Subscribe to all the latest releases from Accesswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Accesswire
VisiRose Introduces Revolutionary Therapy for Severe Eye Infections10.12.2024 07:30:00 CET | Press Release
Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals KNOXVILLE, TN / ACCESSWIRE / December 10, 2024 / VisiRose, a clinical-stage biotechnology company, is introducing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive investigational treatment for infectious keratitis and other serious eye infections developed by the University of Miami Miller School of Medicine's Bascom Palmer Eye Institute (BPEI). VisiRose, a newly launched company of Provectus Biopharmaceuticals (OTCQB:PVCT) and the University, is focused on commercializing this innovative ocular research by combining a formulation of Provectus's pharmaceutical-grade bioactive synthetic small molecule Rose Bengal Sodium (RBS) and BPEI's light-based medical device to treat eye infections caused by bacteria, fungi, and parasites. RB PDAT offers a potential solution to the growing global problem of antimicrobial resistance (AMR), providing a broad-spectrum ocular thera
Young Girl Discovers a 3,500-year-old Egyptian Amulet9.12.2024 07:40:00 CET | Press Release
During a family trip near an archaeological site in Hod Hasharon, 12-year-old Dafna Filshteiner found an ancient scarab. LONDON, UK / ACCESSWIRE / December 9, 2024 / Dafna Filshteiner, age 12, was recently hiking below the ancient site of Tel Qana in Hod Hasharon, when suddenly, to her surprise, she discovered an unusual find a beetle-like stone used as an Egyptian amulet about 3,500 years ago. "I was looking down at the ground to find porcupine needles and smooth pebbles," she says. "And suddenly I picked up an interesting stone. I showed it to my mother, and she said it was just an ordinary stone or a bead. But then I saw a decoration and stubbornly insisted it was more than that, so we searched on the Internet. There, we identified more photos of stones similar to what we had found. We realized that it was something special and immediately called the Antiquities Authority." The family turned to Mor Wiesel, an archaeologist at the Israel Antiquities Authority, who thanked Dafna and h
Loar Announces Launch of Public Offering9.12.2024 06:30:00 CET | Press Release
WHITE PLAINS, NY / ACCESSWIRE / December 9, 2024 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today that it has launched the roadshow for the public offering of 4,750,000 shares of its common stock, including 1,583,333 shares offered by certain stockholders and 3,166,667 shares offered by Loar. In addition, such selling stockholders expect to grant the underwriters a 30-day option to purchase up to 712,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Loar intends to use the net proceeds from this offering for repayment of borrowings outstanding under its credit agreement and, to the extent of any remaining proceeds, for general corporate purposes, including working capital. Loar will not receive any of the proceeds from the sale of common stock offered by the selling stockholders, including any common stock sold pursuant to any exercise by the underwriters of their option to purchase additional shares. Jefferies and
ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium6.12.2024 12:30:00 CET | Press Release
TORONTO, ON / ACCESSWIRE / December 6, 2024 / ProteinQure, the leading company in computational design of peptide therapeutics, will be presenting compelling new data on the progress of their lead triple negative breast cancer (TNBC) drug PQ203 (December 12, 2024 presentation ID: P4-12-17) at the 2024 San Antonio Breast Cancer Symposium. PQ203 is a novel Peptide Drug Conjugate composed of a Sortilin receptor targeting peptide conjugated to the cytotoxic agent monomethyl auristatin E. The Sortiin receptor is expressed in a high percentage of diseased tissue from TNBC patients and as such represents an innovative treatment for this challenging sub-type of breast cancer. ProteinQure has recently generated data that PQ203 exhibits potent efficacy in a patient-derived xenograft (PDX) model resistant to Sacituzumab Govitecan (Trodelvy™), an antibody drug conjugate that is the emerging standard of care for metastatic TNBC. Additionally, PQ203 has shown an encouraging safety profile. Based on
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 20245.12.2024 09:10:00 CET | Press Release
Live webcast discussion featuring internationally renowned Glioblastoma Multiforme (GBM) Key Opinion Leaders Company committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure Register for the event here HOUSTON, TX / ACCESSWIRE / December 5, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it will host a Virtual Analyst & Investor Day on Wednesday, December 11th from 11:30 AM - 1:00 PM ET. For the event, John Climaco, Chief Executive Officer, Sandra Silberman, MD, PhD, Chief Medical Officer and Zena Muzyczenko, Vice President of Clinical Operations at CNS Pharmaceuticals will be joined by Key Opinion Leaders: Michael Weller, Prof. Dr. med. Director of Department, Department of Neurology, Universitatsspital, Zur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom